Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive ChemotherapyHemic and Lymphatic Diseases, Neoplasms by Histologic Type, acute myeloid leukemia, hematologic disorder, leukemia, myelodysplastic syndrome with excess blasts-2, myeloid leukemia, neoplasmActive, not recruitingPhase 32026-09-22NCT03839771

2 results · Page 1 of 1

Swipe the table sideways for more columns.

181 results · Page 1 of 8

Swipe the table sideways for more columns.

Research sitesCityCountryLinked trials
AT-Graz-MEDUNIGRAZGrazAustria2
AT-Innsbruck-IMEDInnsbruckAustria2
AT-Linz-ORDENSKLINIKUMLinzAustria3
AT-Vienna-HANUSCHViennaAustria4
AU-Adelaide-FLINDERSAdelaideAustralia3
AU-Adelaide-RAHAdelaideAustralia4
AU-Brisbane-PAHBrisbaneAustralia3
AU-Camperdown-RPACamperdownAustralia3
AU-Canberra-CANBERRAHOSPITALCanberraAustralia1
AU-Douglas-TOWNSVILLEDouglasAustralia3
AU-Hobart TAS-RHOBARTHobartAustralia2
AU-Launceston TAS-LAUNCESTONLauncestonAustralia1
AU-Melbourne-ALFREDMelbourneAustralia4
AU-Melbourne-AUSTINMelbourneAustralia3
AU-Melbourne-MONASHMelbourneAustralia5
AU-Melbourne-RMELBOURNEMelbourneAustralia2
AU-Melbourne-SVHMMelbourneAustralia3
AU-Perth-FSHPerthAustralia3
AU-Perth-RPHPerthAustralia2
AU-Perth-SCGHPerthAustralia3
AU-Sydney-CONCORDSydneyAustralia2
AU-Sydney-RNSHSydneyAustralia4
AU-Sydney-SVHSSydneyAustralia1
AU-Sydney-WSAHSydneyAustralia3
AU-Waratah-CALVARYMATERWaratahAustralia2